Sumitomo Pharma Statistics

Total Valuation

Sumitomo Pharma has a market cap or net worth of JPY 230.03 billion. The enterprise value is 520.40 billion.

Market Cap	230.03B
Enterprise Value	520.40B

Important Dates

The next estimated earnings date is Friday, January 31, 2025.

Earnings Date	Jan 31, 2025
Ex-Dividend Date	n/a

Share Statistics

Sumitomo Pharma has 397.29 million shares outstanding. The number of shares has decreased by -0.00% in one year.

Current Share Class	n/a
Shares Outstanding	397.29M
Shares Change (YoY)	-0.00%
Shares Change (QoQ)	-0.00%
Owned by Insiders (%)	0.06%
Owned by Institutions (%)	15.17%
Float	180.06M

Valuation Ratios

PE Ratio	n/a
Forward PE	64.60
PS Ratio	0.67
PB Ratio	2.01
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-1.86
EV / Sales	1.52
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-7.09

Financial Position

The company has a current ratio of 0.64, with a Debt / Equity ratio of 3.41.

Current Ratio	0.64
Quick Ratio	0.35
Debt / Equity	3.41
Debt / EBITDA	n/a
Debt / FCF	-5.30
Interest Coverage	-4.97

Financial Efficiency

Return on equity (ROE) is -106.19% and return on invested capital (ROIC) is -26.63%.

Return on Equity (ROE)	-106.19%
Return on Assets (ROA)	-17.76%
Return on Capital (ROIC)	-26.63%
Revenue Per Employee	68.81M
Profits Per Employee	-56.12M
Employee Count	4,980
Asset Turnover	0.35
Inventory Turnover	1.30

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +35.60% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+35.60%
50-Day Moving Average	599.46
200-Day Moving Average	483.07
Relative Strength Index (RSI)	46.92
Average Volume (20 Days)	2,291,585

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Sumitomo Pharma had revenue of JPY 342.67 billion and -279.46 billion in losses. Loss per share was -703.41.

Revenue	342.67B
Gross Profit	204.08B
Operating Income	-276.82B
Pretax Income	-299.39B
Net Income	-279.46B
EBITDA	-244.02B
EBIT	-276.82B
Loss Per Share	-703.41

Full Income Statement

Balance Sheet

The company has 99.08 billion in cash and 389.38 billion in debt, giving a net cash position of -290.30 billion or -730.69 per share.

Cash & Cash Equivalents	99.08B
Total Debt	389.38B
Net Cash	-290.30B
Net Cash Per Share	-730.69
Equity (Book Value)	114.24B
Book Value Per Share	287.37
Working Capital	-172.25B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -62.84 billion and capital expenditures -10.58 billion, giving a free cash flow of -73.43 billion.

Operating Cash Flow	-62.84B
Capital Expenditures	-10.58B
Free Cash Flow	-73.43B
FCF Per Share	-184.81

Full Cash Flow Statement

Margins

Gross margin is 59.56%, with operating and profit margins of -80.78% and -81.55%.

Gross Margin	59.56%
Operating Margin	-80.78%
Pretax Margin	-87.37%
Profit Margin	-81.55%
EBITDA Margin	-71.21%
EBIT Margin	-80.78%
FCF Margin	n/a

Dividends & Yields

Sumitomo Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.00%
Shareholder Yield	0.00%
Earnings Yield	-121.49%
FCF Yield	-31.92%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Sumitomo Pharma has an Altman Z-Score of -0.84. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.84
Piotroski F-Score	n/a